CN101454000A - 含有氨基酸组合物的抗疲劳剂 - Google Patents
含有氨基酸组合物的抗疲劳剂 Download PDFInfo
- Publication number
- CN101454000A CN101454000A CNA2007800195101A CN200780019510A CN101454000A CN 101454000 A CN101454000 A CN 101454000A CN A2007800195101 A CNA2007800195101 A CN A2007800195101A CN 200780019510 A CN200780019510 A CN 200780019510A CN 101454000 A CN101454000 A CN 101454000A
- Authority
- CN
- China
- Prior art keywords
- weight portion
- fatigue
- amino acid
- weight
- antifatigue
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001413 amino acids Chemical class 0.000 title claims abstract description 82
- 239000000203 mixture Substances 0.000 title claims abstract description 64
- 230000002929 anti-fatigue Effects 0.000 title claims abstract description 44
- 239000003795 chemical substances by application Substances 0.000 title abstract description 6
- 229940024606 amino acid Drugs 0.000 claims abstract description 82
- 235000001014 amino acid Nutrition 0.000 claims abstract description 81
- 206010049565 Muscle fatigue Diseases 0.000 claims abstract description 19
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims abstract description 18
- 239000004471 Glycine Substances 0.000 claims abstract description 9
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims abstract description 9
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims abstract description 9
- 235000004279 alanine Nutrition 0.000 claims abstract description 9
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims abstract description 9
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims abstract description 8
- 239000004472 Lysine Substances 0.000 claims abstract description 8
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims abstract description 8
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims abstract description 7
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims abstract description 7
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims abstract description 7
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims abstract description 7
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims abstract description 7
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims abstract description 7
- 239000004473 Threonine Substances 0.000 claims abstract description 7
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims abstract description 7
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims abstract description 7
- 229960000310 isoleucine Drugs 0.000 claims abstract description 7
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims abstract description 7
- 239000004474 valine Substances 0.000 claims abstract description 7
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims abstract description 5
- 230000000694 effects Effects 0.000 claims description 32
- 230000009471 action Effects 0.000 claims description 21
- 230000001537 neural effect Effects 0.000 claims description 17
- 210000004369 blood Anatomy 0.000 claims description 14
- 239000008280 blood Substances 0.000 claims description 14
- 239000000090 biomarker Substances 0.000 claims description 11
- 238000011156 evaluation Methods 0.000 claims description 7
- 102000004452 Arginase Human genes 0.000 claims description 5
- 108700024123 Arginases Proteins 0.000 claims description 5
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims description 4
- 210000005036 nerve Anatomy 0.000 abstract description 3
- 239000004475 Arginine Substances 0.000 abstract 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 abstract 1
- 206010016256 fatigue Diseases 0.000 description 60
- 235000013305 food Nutrition 0.000 description 15
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 10
- 238000000034 method Methods 0.000 description 9
- 239000000843 powder Substances 0.000 description 9
- 208000019914 Mental Fatigue Diseases 0.000 description 8
- 238000011084 recovery Methods 0.000 description 8
- 235000013336 milk Nutrition 0.000 description 7
- 239000008267 milk Substances 0.000 description 7
- 210000004080 milk Anatomy 0.000 description 7
- 102000003814 Interleukin-10 Human genes 0.000 description 6
- 108090000174 Interleukin-10 Proteins 0.000 description 6
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 229940076144 interleukin-10 Drugs 0.000 description 6
- 102100037850 Interferon gamma Human genes 0.000 description 5
- 108010074328 Interferon-gamma Proteins 0.000 description 5
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 5
- 229920002472 Starch Polymers 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 229960000890 hydrocortisone Drugs 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- 235000019198 oils Nutrition 0.000 description 5
- 235000019698 starch Nutrition 0.000 description 5
- 239000008107 starch Substances 0.000 description 5
- 235000015961 tonic Nutrition 0.000 description 5
- 230000001256 tonic effect Effects 0.000 description 5
- 102000011632 Caseins Human genes 0.000 description 4
- 108010076119 Caseins Proteins 0.000 description 4
- 102000004407 Lactalbumin Human genes 0.000 description 4
- 108090000942 Lactalbumin Proteins 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 230000000052 comparative effect Effects 0.000 description 4
- 230000033001 locomotion Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 3
- 235000013361 beverage Nutrition 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 235000019197 fats Nutrition 0.000 description 3
- 239000012467 final product Substances 0.000 description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000011707 mineral Substances 0.000 description 3
- 235000010755 mineral Nutrition 0.000 description 3
- 210000002381 plasma Anatomy 0.000 description 3
- 241000894007 species Species 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- JDHILDINMRGULE-LURJTMIESA-N N(pros)-methyl-L-histidine Chemical compound CN1C=NC=C1C[C@H](N)C(O)=O JDHILDINMRGULE-LURJTMIESA-N 0.000 description 2
- 239000005862 Whey Substances 0.000 description 2
- 102000007544 Whey Proteins Human genes 0.000 description 2
- 108010046377 Whey Proteins Proteins 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 2
- 235000014121 butter Nutrition 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 235000015165 citric acid Nutrition 0.000 description 2
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 2
- 230000002354 daily effect Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 229960003512 nicotinic acid Drugs 0.000 description 2
- 235000001968 nicotinic acid Nutrition 0.000 description 2
- 239000011664 nicotinic acid Substances 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000000630 rising effect Effects 0.000 description 2
- -1 suspensoid Substances 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- LUTLAXLNPLZCOF-UHFFFAOYSA-N 1-Methylhistidine Natural products OC(=O)C(N)(C)CC1=NC=CN1 LUTLAXLNPLZCOF-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- BRMWTNUJHUMWMS-UHFFFAOYSA-N 3-Methylhistidine Natural products CN1C=NC(CC(N)C(O)=O)=C1 BRMWTNUJHUMWMS-UHFFFAOYSA-N 0.000 description 1
- 102100030840 AT-rich interactive domain-containing protein 4B Human genes 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 238000011814 C57BL/6N mouse Methods 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 102100034279 Calcium-binding mitochondrial carrier protein Aralar2 Human genes 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 101000792935 Homo sapiens AT-rich interactive domain-containing protein 4B Proteins 0.000 description 1
- 241001562081 Ikeda Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 108010063045 Lactoferrin Proteins 0.000 description 1
- 102000010445 Lactoferrin Human genes 0.000 description 1
- 102000008192 Lactoglobulins Human genes 0.000 description 1
- 108010060630 Lactoglobulins Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- SUHOOTKUPISOBE-UHFFFAOYSA-N O-phosphoethanolamine Chemical compound NCCOP(O)(O)=O SUHOOTKUPISOBE-UHFFFAOYSA-N 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 108010073771 Soybean Proteins Proteins 0.000 description 1
- 241000282894 Sus scrofa domesticus Species 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 229930003448 Vitamin K Natural products 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 1
- 229940000635 beta-alanine Drugs 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 229960004106 citric acid Drugs 0.000 description 1
- 108010084210 citrin Proteins 0.000 description 1
- 235000017471 coenzyme Q10 Nutrition 0.000 description 1
- 229940110767 coenzyme Q10 Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000014510 cooky Nutrition 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 235000021323 fish oil Nutrition 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000013350 formula milk Nutrition 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000004519 grease Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 239000000413 hydrolysate Substances 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000000366 juvenile effect Effects 0.000 description 1
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229940078795 lactoferrin Drugs 0.000 description 1
- 235000021242 lactoferrin Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 229940040145 liniment Drugs 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 230000001483 mobilizing effect Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 239000002417 nutraceutical Substances 0.000 description 1
- 235000021436 nutraceutical agent Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 235000011837 pasties Nutrition 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 235000019710 soybean protein Nutrition 0.000 description 1
- 235000011496 sports drink Nutrition 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229960000716 tonics Drugs 0.000 description 1
- 230000001228 trophic effect Effects 0.000 description 1
- 229960004747 ubidecarenone Drugs 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 239000011712 vitamin K Substances 0.000 description 1
- 150000003721 vitamin K derivatives Chemical class 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940046001 vitamin b complex Drugs 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 229940046010 vitamin k Drugs 0.000 description 1
- 235000008939 whole milk Nutrition 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 235000021249 α-casein Nutrition 0.000 description 1
- 235000021241 α-lactalbumin Nutrition 0.000 description 1
- 235000021247 β-casein Nutrition 0.000 description 1
- 235000021246 κ-casein Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nutrition Science (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Obesity (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Mycology (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Non-Alcoholic Beverages (AREA)
Abstract
本发明提供一种能够同时防止肌肉疲劳和神经疲劳的抗疲劳剂。本发明采用含有由特定种类和特定数量的氨基酸组成的氨基酸组合物的抗疲劳剂,能够同时防止肌肉疲劳和神经疲劳。优选含有氨基酸种类和重量比为脯氨酸30-200重量份、甘氨酸60-140重量份、丙氨酸25-260重量份、赖氨酸40-130重量份、色氨酸20-75重量份、组氨酸15-40重量份的氨基酸组合物。优选还含有苏氨酸35-65重量份、酪氨酸15-65重量份、精氨酸25-45重量份的氨基酸组合物,优选还含有缬氨酸30-55重量份、亮氨酸35-60重量份、异亮氨酸25-45重量份的氨基酸组合物。
Description
技术领域
本发明涉及一种含有由特定种类的氨基酸组成氨基酸组合物的抗疲劳剂。
背景技术
对于生活在现代社会的人们来说,“疲劳”这一现象已经渐渐成为不容忽视的现状。根据近年的调查结果显示,全国民的近60%有疲劳感,其中将近40%的人有持续6个月以上的疲劳感。若将其换算为就业人口,则近3000万人的劳动者在伴随持续疲劳感的状态下从事工作。此外,在严重的慢性疲劳的情况下还会给日常生活带来影响。而且,由这些疲劳引起的经济损失,包括康复措施相关的费用在内,可推测为自数千亿日元至一万亿日元规模。
疲劳,从发生来进行分类时,可大致分为急性疲劳和慢性疲劳,前者多以数分钟至数小时为单位发生,通过比较短时间的休息即可恢复。后者为急性疲劳蓄积时,不易恢复,是要通过数日进行恢复,更长时则要以周为单位进行恢复,这样一种水平上的疲劳,像上述那样地长期度过时也就形成了持续6个月以上的疲劳的情况。
此外,从疲劳产生的部位进行分类时,可大致分为肉体疲劳和精神(神经)疲劳。但是,对于这些疲劳虽然能以肌肉疲劳和神经疲劳来进行分类,但从它们的压力来看,实际上相互间通常存在着复杂的关联。因此,以上述的简单分类,并不能找出唯一的应对方法,如果能得到有关这一点的见解,则将能够构建有效的疲劳恢复措施。
作为疲劳防止或恢复的方法,从沐浴等简易的压力缓解方法到药剂给药,对治疗方法进行了种种讨论。这些方法以恢复上述肌肉疲劳和神经疲劳的各种疲劳为目的,但实际中还尚未取得能够同时解除两种疲劳的方法。
同样,这些方法中有包含施予某种药剂或补品的情况。给药时需要根据医生等的诊断或处方等,因此比较繁琐。另一方面,作为补品的食物应对方法,由于其简便且在日常生活中又易于施予,近年来其研究开发、商品开发日益发展,补品市场正不断扩大。例如,以柠檬酸、维生素、辅酶Q10为例的疲劳恢复用的补品在便利店等也有出售。但是,即使是这些补品,也不能明显起到恢复上述肌肉疲劳和神经疲劳的各种疲劳的效果,实际中还未能找到同时解除上述两种疲劳的明确方法。
一方面,主要以提高运动能力为目的而引人注目的、商品名为“VAAM”(明治乳业株式会社制造)的大胡蜂的幼虫分泌的唾液中含有的多种氨基酸组合物,在疲劳恢复上也具有效果(如专利文献1),进而就由此项技术派生出的种种氨基酸组合物的开发也正在进展中。例如专利文献2中,公开了一种快速恢复肌肉本身的疲劳以及其伴随的倦怠感等精神疲劳的氨基酸组合物。
此外,有关以BCAA著称的缬氨酸、亮氨酸、异亮氨酸,认为它们中除了具有提高运动能力的用途以外,还具有中枢神经系统的疲劳(脑力疲劳)预防或脑疲劳恢复效果,从而提供了使用上述氨基酸的中枢神经系统用疲劳预防/恢复剂(专利文献3)。
另一方面,由一些有关疲劳的研究结果显示,疲劳会伴随着某种氨基酸的血中浓度的下降和向特定组织的摄入。例如,非专利文献1中公开了对于采用自行车的方式施加了长时间负荷的人来说,脯氨酸、甘氨酸、丙氨酸等氨基酸被有意消耗而降低。
此外,非专利文献2中,在运动时有无补充碳水化合物的条件下,对血浆中成分的浓度变化进行了讨论。该文献中显示甘氨酸、丙氨酸、赖氨酸、苏氨酸、组氨酸在血浆中的浓度下降,尤其是组氨酸的下降率较大。
非专利文献3中也公开了运动时有无供给食物的体系中,有关各种血浆中成分的浓度变化的研究结果。其中尤其公开了色氨酸的浓度下降率较大。
与各氨基酸的含量下降有关的运动和疲劳现象间的因果关系尚未明确,但是能推测出能量代谢循环中这些氨基酸是存在着某些关联并被消耗的。因此,容易想到通过补充这些浓度下降的氨基酸来恢复疲劳。但是,肉体疲劳、精神疲劳后,只通过补充上述氨基酸也无法恢复疲劳,同样即使事前摄入这些氨基酸,也不能确知是否能取得疲劳恢复的效果。
专利文献1:专利第2518692号公报
专利文献2:特开平8-198748号公报
专利文献3:再表2002/034257号公报
非专利文献1:G..Ahlborg et al,The Journal of Clinical Investigation,第53卷,1974年4月,p.1080-1090
非专利文献2:T.L.bazzare et al,Journal of the American College ofNutrition,1992年,第11卷,第5期,p.501-511
非专利文献3:A.H.Forslund et al,Am.J.Physiol Endocrinol Metab.,2000年,第278卷,p.857-867
发明内容
发明要解决的技术问题
如上所述,这些以往的氨基酸组合物,以运动能力的提高为主要目的,从抗疲劳效果、防止疲劳的观点的探讨研究还并不充分。此外,也有专门主张有关疲劳恢复或防止的效果的技术,但它们对肌肉疲劳和神经疲劳的防止效果的探讨研究都不充分,还称不上能解决问题。而且,这些以往的氨基酸组合物必须提供多种且多量的氨基酸作为组合物,必然暗藏着高成本的问题。
本发明人等锐意研究的结果,用过去没有的组成和重量比构成氨基酸组合物,以弥补以往的疲劳防止效果的不足,而完成了本发明。
因此,本发明的目的是提供一种抗疲劳剂,其含有由特定种类的特定量的氨基酸组成的氨基酸组合物的抗疲劳剂。
解决上述技术问题的技术方案
即,本发明提供一种含有由如下的氨基酸组成的氨基酸组合物的抗疲劳剂:
脯氨酸 30-200重量份;
甘氨酸 60-140重量份;
丙氨酸 25-260重量份;
赖氨酸 40-130重量份;
色氨酸 20-75重量份;
组氨酸 15-40重量份。
此外,抗疲劳剂优选地在上述构成的氨基酸组合物中,进一步含有如下的氨基酸:
苏氨酸 35-65重量份;
酪氨酸 15-65重量份;
精氨酸 25-45重量份。
此外,组合物抗疲劳剂优先地在上述构成的氨基酸组合物中,进一步含有如下的氨基酸:
缬氨酸 30-55重量份;
亮氨酸 35-60重量份;
异亮氨酸 25-45重量份。
进而,本发明所述的抗疲劳剂,同时防止肌肉疲劳和神经疲劳。
此外,本发明所述的抗疲劳剂,通过行动量测定来评价肌肉疲劳,通过血中生物标记测定来评价神经疲劳。
进而,本发明所述的抗疲劳剂,在采用行动量测定的评价中,当非给药组的行动量为100时,给药组的行动量(相对值)在110以上,并且,在采用血中生物标记测定的评价中,当非给药组的测定浓度为100时,给药组的测定浓度(相对值)在96以下,则评价为具有肌肉疲劳和神经疲劳的防止效果。
发明的效果
本发明的抗疲劳剂中使用的组合物,为采用以往没有的组成和重量比的氨基酸组合物。由此,对于以往不完善的疲劳防止能够得到更高的效果。即通过本发明首次做到同时实际地防止肌肉疲劳和神经疲劳。
本发明中,作为评价体系特别使用了疲劳时的行动量测定和疲劳时的血中生物标记测定的两种评价体系,分别作为肌肉疲劳和精神疲劳的指标。其结果,有关本发明的氨基酸组合物,尤其在两个评价体系中能够取得显著的疲劳防止效果。
此外,本发明,采用比以往的氨基酸组合物更少种类的氨基酸就能够取得更好的疲劳防止效果,因此,减少了制备中必须的原材料的种类,在工业上和经济上都取得了很好的效果。
进而,与以往的氨基酸组合物相比,本发明的抗疲劳剂通过少量的氨基酸就能够取得较高的疲劳防止效果,因此从这一点来说,在工业上和经济上都取得了很好的效果。此外,为了取得与以往同等的效果而进行调制时,各种氨基酸的使用量少,当将其应用在饮料等中而进行调制时,作为饮料,可实现低容量化,特别是当制成运动饮料等携带用饮料时尤其有效。
本发明的最佳实施方式
以下,对本发明进行具体说明,但是本发明不局限于如下所述的各个实施方式。
本发明的抗疲劳剂中所含有的氨基酸组合物,优选含有按如下重量比的氨基酸。
脯氨酸 30-200重量份;
甘氨酸 60-140重量份;
丙氨酸 25-260重量份;
赖氨酸 40-130重量份;
色氨酸 20-75重量份;
组氨酸 15-40重量份。
上述组成的氨基酸组合物,优选地还含有如下的氨基酸。
苏氨酸 35-65重量份;
酪氨酸 15-65重量份;
精氨酸 25-45重量份。
此外,上述组合物的氨基酸组合物,优选地还含有如下的氨基酸。
缬氨酸 30-55重量份;
亮氨酸 35-60重量份;
异亮氨酸 25-45重量份。
本发明的抗疲劳剂中所含有的氨基酸组合物,优选含有按如下的重量比的如下的氨基酸。
脯氨酸 40-150重量份;
甘氨酸 75-110重量份;
丙氨酸 30-220重量份;
赖氨酸 55-95重量份;
色氨酸 25-65重量份;
组氨酸 20-35重量份;
苏氨酸 35-65重量份;
酪氨酸 15-65重量份;
精氨酸 25-45重量份。
此外,抗疲劳剂优选地含有只由这9种氨基酸组成的氨基酸组合物抗疲劳剂。
进而,本发明的抗疲劳剂中所含有的氨基酸组合物,还优选含有按如下的重量比的如下的氨基酸。
脯氨酸 40-150重量份;
甘氨酸 75-110重量份;
丙氨酸 30-220重量份;
赖氨酸 55-95重量份;
色氨酸 25-65重量份;
组氨酸 20-35重量份;
缬氨酸 30-55重量份;
亮氨酸 35-60重量份;
异亮氨酸 25-45重量份。
此外,抗疲劳剂优选地含有只由这9种氨基酸组成的氨基酸组合物抗疲劳剂。
此外,本发明的抗疲劳剂中所含有的氨基酸组合物,还优选含有按如下的重量比的如下的氨基酸。
脯氨酸 40-120重量份;
甘氨酸 60-85重量份;
丙氨酸 25-170重量份;
赖氨酸 40-75重量份;
色氨酸 20-50重量份;
组氨酸 20-30重量份;
苏氨酸 35-55重量份;
酪氨酸 15-55重量份;
精氨酸 25-40重量份;
缬氨酸 30-40重量份;
亮氨酸 35-50重量份;
异亮氨酸 25-40重量份。
本发明中,抗疲劳剂特别优选地含有只由这12种氨基酸组成的氨基酸组合物抗疲劳剂。
再者,在上述构成的氨基酸组合物中,酪氨酸进一步优选地为35-55重量份。
此外,本发明的抗疲劳剂,通过疲劳时的行动量测定和疲劳时的血中生物标记测定的两种评价体系,在肌肉疲劳及神经疲劳的两方面,被评价为具有疲劳防止效果。
采用行动量测定的评价,如,对给药组(施予氨基酸组合物)和非给药组(对照组)的两组,采用活动平板等施加运动负荷,分别测定两组的行动量,将非给药组的行动量设定为100时,计算出给药组的相对行动量。给药组的行动量(相对值)超过100时,优选地为110以上,更优选地为120以上,最优选地为190以上时,施予的氨基酸组合物,可以评价为具有肌肉疲劳的防止效果。此外,给药组的行动量(相对值)的数值越大,肌肉疲劳的防止效果可以评价为越高。
通过血中生物标记测定的评价,如,对给药组(施予氨基酸组合物)和非给药组的两组,采用活动平板等施加运动负荷,经过一定时间后进行采血,分别测定两组的血中生物标记的浓度,将非给药组的测定浓度设定为100时,计算出给药组的相对测定浓度。以任意的血中生物标记(含有皮质醇、干扰素-γ(IFN-γ)、白细胞介素-10(IL-10))为指标时,给药组的的测定浓度(相对值)不满100时,优选地,当为96以下时,可以评价为具有神经疲劳的防止效果。
特别是以皮质醇为指标时,给药组的测定浓度(相对值),优选地,为95以下,更优选地,为80以下时,可以评价为具有神经疲劳的防止效果。其次,以IFN-γ为指标时,给药组的测定浓度(相对值),优选地为60以下,更优选地为45以下时,可以评价为具有神经疲劳的防止效果。再者,以IL-10I为指标时,给药组的测定浓度(相对值),优选地为70以下,更优选地为50以下时,可以评价为具有神经疲劳的防止效果。
此外,给药组的测定浓度(相对值)的数值越小,神经疲劳的防止效果可以评价为越高。
本发明的抗疲劳剂中除了上述的氨基酸外,根据需要还可含有蛋氨酸(优选0.3-0.7mol%,更优选0.4-0.6mol%)、天冬氨酸(优选0.1-0.3mol%)、牛磺酸(优选3mol%以下)、磷酸乙醇胺(优选2mol%以下)、胱氨酸(优选0.5mol%以下)、β-丙氨酸(优选1mol%以下)、γ-氨基丁酸(优选0.5mol%以下)、鸟氨酸或乙醇胺(优选3mol%以下)、氨(优选2mol%以下)、1-甲基组氨酸(优选3mol%以下)、3-甲基组氨酸(优选1mol%以下)。本发明中使用的氨基酸组合物中的氨基酸特别优选L-氨基酸。
本发明中使用的各种氨基酸,优选各个单品均为高纯度的氨基酸。如,使用“食品添加物公定书”中规定纯度以上的氨基酸。此外,作为这些氨基酸,也可以使用生理学上所能允许的盐的形态。
制造本发明的氨基酸组合物时,将市面上出售的上述氨基酸按照上述的既定比例混合即可。此外,作为溶液使用时,将其溶解在蒸馏水中即可。通常以粉末状混合均匀而作为组合物备用,使用时溶解在蒸馏水中即可。制造、保存本发明的组合物的温度没有特别的限定,但优选地在室温以下制造、保存。
作为本发明的抗疲劳剂的施予形式,可以列举如片剂、包衣片剂、胶囊剂、颗粒剂、散剂、溶液、糖浆剂、乳液等经口施予形式。上述的各种制剂,可以按照常规的方法在本发明的氨基酸组合物中使用赋形剂、粘合剂、崩解剂、润滑剂、着色剂、矫味矫臭剂、助溶剂、混悬剂、涂膜剂等医药制剂技术领域中通用的已知助剂来制剂。
作为本发明的抗疲劳剂的主成分的氨基酸组合物安全性很高,可以大范围设定其给药量。一般,要考虑给药途径、给药对象动物(包括人)的年龄、体重、症状等各种因素,适当地进行设定。本发明不限定于此,但作为有效成分,以1g-8g/kg/day为合适。
本发明的组合物不只在防止疲劳时作为事前施予的抗疲劳剂使用,还可以在感到疲劳时作为事后施予的疲劳恢复剂使用,0.3-6.0重量%溶液,以每次施予100-500ml,每日1-3次为佳。作为注射剂的0.3-6.0重量%溶液,每次施予100-400ml,优选150-300ml。
此外,本发明的抗疲劳剂,可以用经口施予或非经口施予(肌肉内、皮下、静脉内、栓剂、经皮等)的任一方式进行。
具有上述组成的本发明的抗疲劳剂也可以做成包括特定保健用食品等的特别用途食品,也可将本发明的抗疲劳剂用在食品组合物中,作为营养功能食品等功能性食品直接摄取,可以容易地取得疲劳防止效果。
具体地,作为食品组合物使用时,各种饮食品(牛奶、清凉饮料、发酵乳、酸奶、奶酪、面包、饼干、苏打饼干、比萨饼、调制奶粉、流质食品、患者用食品、婴幼儿奶粉等食品、哺乳妇女用奶粉等食品、营养食品等)中,按其组成添加本发明的抗疲劳剂,而摄取之。进一步,例如与其他食品或食品成分混合等,可以按照通常的食品组合物的常规方法使用。此外,对其性状而言,通常使用的饮食品的状态,如,固体状(粉末、颗粒状及其它)、糊状、液状甚至悬浮状均可。
作为食品组合物使用时,对其它的成分也没有特别的限定,但上述食品组合物,例如饮食物中也可使用水、蛋白质、糖质、脂质、维生素类、矿物质类、有机酸、有机碱、果汁、香料类等作为成分。作为蛋白质,可以列举如全脂奶粉、脱脂奶粉、部分脱脂奶粉、酪朊、乳清粉、乳清蛋白、乳清蛋白浓缩物、乳清蛋白分离物、α-酪蛋白、β-酪蛋白、κ-酪蛋白、β-乳球蛋白、α-乳清蛋白、乳铁蛋白、大豆蛋白、鸡蛋蛋白、肉蛋白等的动植物性蛋白、它们的水解物;黄油、乳清矿物质、奶油、乳清、非蛋白态氮、唾液酸、磷脂质、乳糖等各种乳原料成分等。可以列举糖类、加工淀粉(除了糊精以外,还有可溶性淀粉、英国淀粉、氧化淀粉、淀粉酯、淀粉醚等)、食物纤维等。作为脂质,可以列举如猪油、鱼油等、它们的分离油、氢化油、酯交换油等动物性油脂;棕榈油、红花油、玉米油、菜籽油、椰子油、它们的分离油、氢化油、酯交换油等植物性油脂等。作为维生物类,可以列举如维生素A、胡萝卜素类、维生素B族、维生素C、维生素D族、维生素E、维生素K族、维生素P、维生素Q、烟酸、烟碱酸、泛酸、生物素、肌醇、胆碱、叶酸等,作为矿物质类,可以列举如钙、钾、镁、钠、铜、铁、锰、锌、硒等。作为有机酸,可以列举如苹果酸、枸橼酸、乳酸、酒石酸等。上述的成分可以两种以上组合使用,也可利用合成品和/或富含上述成分的食品。
实施例
以下,列举了本发明的实施例,对本发明进行了详细的说明,但是本发明不局限于这些具体的实施例。
将小鼠(雄、8周龄,C57BL/6N、在饲养环境23±3℃下明暗12小时循环)按照各组的体重尽可能均匀地进行分配,分成每组3-4只小鼠组成的受试组(实施例)和对照组(对比例)。不让小鼠绝食,强制经口施予本发明的抗疲劳剂或用作控制剂的生理盐水。给药1小时后通过活动平板运动试验(以25m/min进行60分钟)施加运动负荷。
此外,给药量以氨基酸换算后为500mg/kg体重(以10μL/g体重的量施予5%的悬乳液)。其中施予的本发明的抗疲劳剂的氨基酸组成如表1所示(氨基酸组成的数值用重量份表示)。
【实验1】疲劳时的行动量测量
采用活动平板运动试验施加运动负荷后进行行动量测定。在红色灯照明下测定30分钟内行动的总路程。以控制组(对比例1)的行动量为100时,表示各个实施例中的行动量。即,可以认为数值越大,肌肉疲劳越少。
【实验2】疲劳时的血中生物标记测定
平板活动运动试验结束后,在经过一定时间后进行采血,测定作为血液中的免疫学指标的皮质醇、干扰素-γ(IFN-γ)、白细胞介素-10(IL-10)。以控制组的浓度为100时,表示各个实施例中的浓度。即,可以认为数值越小,疲劳感越低,精神疲劳越小。
此外,上述评价方法是根据大阪市立大学医学部生化学·分子病态学讲座井上正康教授等人在2005年的日本生化学会上发表的方法(演讲题目:运动疲劳的免疫应答系统的性差解析,生化学,2005,第77卷,p.1056)进行的。
表1
实施例1 | 实施例2 | 实施例3 | 实施例4 | 实施例5 | 实施例6 | 对比例1 | |
Pro | 53.63 | 197.95 | 43.29 | 143.76 | 34.00 | 115.40 | — |
Gly | 101.74 | 136.83 | 82.12 | 99.37 | 64.47 | 79.77 | — |
Ala | 256.56 | 52.05 | 207.06 | 37.80 | 162.59 | 30.34 | — |
Lys | 74.27 | 120.40 | 59.94 | 87.44 | 47.06 | 70.19 | — |
Trp | 69.18 | 42.85 | 55.82 | 31.12 | 43.82 | 24.98 | — |
His | 32.85 | 38.14 | 26.53 | 27.70 | 20.82 | 22.24 | — |
Thr | — | — | 41.76 | 59.24 | 41.76 | 47.55 | — |
Tyr | — | — | 41.82 | 59.32 | 41.82 | 47.62 | — |
Arg | — | — | 29.94 | 42.47 | 29.94 | 34.09 | — |
Val | — | — | — | — | 33.59 | 38.24 | — |
Leu | — | — | — | — | 39.41 | 44.87 | — |
Ile | — | — | — | — | 28.94 | 32.95 | — |
氨基酸种类数 | 6种 | 6种 | 9种 | 9种 | 12种 | 12种 | 0种 |
行动量 | 110 | 119 | 133 | 122 | 269 | 190 | 100 |
IFN-γ | 56 | 38 | 58 | 45 | 53 | 39 | 100 |
皮质醇 | 79 | 76 | 80 | 95 | 34 | 30 | 100 |
IL-10 | 96 | 61 | 64 | 92 | 47 | 52 | 100 |
本发明的实施例1-6的抗疲劳剂,与对比例1相比,在施加活动平板运动试验的运动负荷后还能够构进行运动,可知肌肉疲劳的防止效果高。特别是实施例5和实施例6,表现出了非常高的运动后的行动量。
此外,基于血中生物标记测定的结果,在本发明的实施例1-6中皮质醇、IFN-γ、IL-10的浓度上升明显得到了抑制。由于这些化合物的浓度的提高,与疲劳感的上升成比例,所以能够作为精神疲劳的代替指标进行评价。即,可以看出本发明的实施例1-6,在精神疲劳的防止效果上也具有很好的效果。进一步而言,可以看出该倾向在实施例5和实施例6中表现更显著。
工业实用性
综上所述,本发明涉及的含有氨基酸组合物的抗疲劳剂,能同时防止肌肉疲劳和精神疲劳两种疲劳,提供很高的疲劳防止效果。此外,与以往的以运动能力等的提高为目的的氨基酸组合物相比,由更少种氨基酸种类组成,使得在制造中减少了必需的原材料种类,在工业上和经济上都取得了优良的效果。因此,生产上的利用价值很高。
Claims (6)
1、一种抗疲劳剂,含有由如下的氨基酸组成的氨基酸组合物:
脯氨酸 30-200重量份;
甘氨酸 60-140重量份;
丙氨酸 25-260重量份;
赖氨酸 40-130重量份;
色氨酸 20-75重量份;
组氨酸 15-40重量份。
2、如权利要求1所述的抗疲劳剂,还含有如下的氨基酸:
苏氨酸 35-65重量份;
酪氨酸 15-65重量份;
精氨酸 25-45重量份。
3、如权利要求1或2所述的抗疲劳剂,还含有如下的氨基酸:
缬氨酸 30-55重量份;
亮氨酸 35-60重量份;
异亮氨酸 25-45重量份。
4、如权利要求1-3任一所述的抗疲劳剂,同时防止肌肉疲劳和神经疲劳。
5、如权利要求4所述的抗疲劳剂,通过行动量测定来评价肌肉疲劳,通过血中生物标记测定来评价神经疲劳。
6、如权利要求5所述的抗疲劳剂,在采用行动量测定的评价中,当非给药组的行动量设定为100时,给药组的行动量(相对值)在110以上,并且,在采用血中生物标记测定的评价中,当非给药组的测定浓度设定为100时,给药组的测定浓度(相对值)在96以下,则评价为具有肌肉疲劳和神经疲劳的防止效果。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP163683/2006 | 2006-06-13 | ||
JP2006163683 | 2006-06-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN101454000A true CN101454000A (zh) | 2009-06-10 |
Family
ID=38831753
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNA2007800195101A Pending CN101454000A (zh) | 2006-06-13 | 2007-06-13 | 含有氨基酸组合物的抗疲劳剂 |
Country Status (4)
Country | Link |
---|---|
JP (2) | JP5775657B2 (zh) |
KR (1) | KR20090019813A (zh) |
CN (1) | CN101454000A (zh) |
WO (1) | WO2007145239A1 (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104509919A (zh) * | 2013-09-30 | 2015-04-15 | 张自力 | 一种功能性营养素饮料 |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5775657B2 (ja) * | 2006-06-13 | 2015-09-09 | 株式会社明治 | アミノ酸組成物を含有する疲労防止剤 |
WO2009057775A1 (ja) * | 2007-10-31 | 2009-05-07 | Meiji Dairies Corporation | アミノ酸組成物を含有する疲労防止剤 |
US8778410B2 (en) | 2008-02-19 | 2014-07-15 | Earnest Medicine Co., Ltd. | Oral or enteral composition useful for recovery of physical functions |
WO2010041647A1 (ja) * | 2008-10-06 | 2010-04-15 | 明治乳業株式会社 | アミノ酸組成物を有効成分として含む持久力向上剤、疲労防止剤、又は疲労回復剤 |
WO2012169600A1 (ja) * | 2011-06-07 | 2012-12-13 | 味の素株式会社 | アミノ酸組成物 |
JP2013060406A (ja) * | 2011-09-15 | 2013-04-04 | Kyowa Hakko Bio Co Ltd | 脳疲労改善用経口剤 |
WO2015053337A1 (ja) * | 2013-10-09 | 2015-04-16 | 味の素株式会社 | ヒスチジンを含有する食品およびその用途 |
JP6496599B2 (ja) * | 2014-06-13 | 2019-04-03 | 花王株式会社 | 筋タンパク質合成シグナル活性化剤 |
JP2016121194A (ja) * | 2016-04-05 | 2016-07-07 | 協和発酵バイオ株式会社 | 脳疲労改善用経口剤 |
EP3466434A4 (en) * | 2016-05-26 | 2020-01-22 | Profeat Biotechnology Co. Ltd. | USE OF A COMPOSITION WITH FERROUS AMINO ACID CHELATE FOR PRODUCING A MEDICINAL PRODUCT FOR REDUCING LACTIC ACID |
WO2019036471A1 (en) * | 2017-08-14 | 2019-02-21 | Axcella Health Inc. | AMINO ACIDS BRANCHED FOR THE TREATMENT OF LIVER DISEASE |
JP7275499B2 (ja) | 2018-08-27 | 2023-05-18 | 味の素株式会社 | 脳機能改善用組成物 |
KR102235563B1 (ko) | 2020-08-26 | 2021-04-02 | (주)이삼오구 | 고함량 아르기닌을 포함하는 피로회복 및 성기능 개선용 조성물 |
JP7414676B2 (ja) * | 2020-09-14 | 2024-01-16 | 株式会社東芝 | 負荷推定装置、方法およびプログラム |
JP7462127B1 (ja) | 2023-08-16 | 2024-04-05 | 株式会社Healthy Body | 筋肥大用組成物 |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5026721A (en) * | 1989-06-05 | 1991-06-25 | Dudrick Stanley J | Amino acid nutritional supplement and regimen for enhancing physical performance through sound nutrition |
JP2518692B2 (ja) * | 1989-06-14 | 1996-07-24 | 理化学研究所 | 筋力持続剤,滋養強壮剤,輸液用剤,栄養補給剤,疲労回復剤及び乳酸生成調節剤 |
JPH0725838A (ja) * | 1993-05-13 | 1995-01-27 | Yotsuba Yuka Kk | 疲労の予防または回復のための経口投与剤 |
JP4009682B2 (ja) * | 1993-05-28 | 2007-11-21 | 独立行政法人理化学研究所 | アドレナリン及びノルアドレナリン分泌促進組成物 |
JP3617102B2 (ja) * | 1995-01-27 | 2005-02-02 | 味の素株式会社 | ヒト筋肉疲労の早期回復効果を有するアミノ酸栄養組成物 |
JP4280310B2 (ja) * | 1995-08-10 | 2009-06-17 | 佐々木化学工業株式会社 | アミノ酸組成剤 |
TW413633B (en) * | 1996-01-09 | 2000-12-01 | Rikagaku Kenkyusho | Amino acid composition |
JP2000009717A (ja) * | 1998-02-27 | 2000-01-14 | Taisho Pharmaceut Co Ltd | 滋養強壮効果の評価方法 |
JP2001226272A (ja) * | 2000-02-18 | 2001-08-21 | Zeria Pharmaceut Co Ltd | クエン酸及びローヤルゼリーを配合した内服液剤 |
JP3838038B2 (ja) * | 2001-02-05 | 2006-10-25 | 株式会社豊田中央研究所 | 心身状態評価方法、商品又は環境の感性的品質の評価方法、評価用測定キット及び商品又は環境の品質表示方法 |
JP2003207495A (ja) * | 2002-01-10 | 2003-07-25 | Toyota Central Res & Dev Lab Inc | 心理状態判定装置 |
JP2004123564A (ja) * | 2002-09-30 | 2004-04-22 | Inst Of Physical & Chemical Res | 中枢機能改善用アミノ酸組成物 |
AU2003271144A1 (en) * | 2002-10-11 | 2004-05-04 | Ajinomoto Co., Inc. | Food compositions for recovery from fatigue |
JP4528925B2 (ja) * | 2003-05-30 | 2010-08-25 | 独立行政法人理化学研究所 | アミノ酸組成物及び補液 |
GB0400031D0 (en) * | 2004-01-03 | 2004-02-04 | Univ Sheffield | Depression treatment |
US20070134156A1 (en) * | 2004-02-17 | 2007-06-14 | Soiken Inc. | Fatigue evaluation apparatus, fatigue evaluation method, and application thereof |
JP2005239579A (ja) * | 2004-02-24 | 2005-09-08 | Ajinomoto Co Inc | 疲労回復剤及び疲労回復用食品 |
JP5775657B2 (ja) * | 2006-06-13 | 2015-09-09 | 株式会社明治 | アミノ酸組成物を含有する疲労防止剤 |
-
2007
- 2007-06-13 JP JP2008521230A patent/JP5775657B2/ja active Active
- 2007-06-13 CN CNA2007800195101A patent/CN101454000A/zh active Pending
- 2007-06-13 KR KR1020087029275A patent/KR20090019813A/ko not_active Application Discontinuation
- 2007-06-13 WO PCT/JP2007/061879 patent/WO2007145239A1/ja active Application Filing
-
2015
- 2015-01-19 JP JP2015008128A patent/JP2015120715A/ja active Pending
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104509919A (zh) * | 2013-09-30 | 2015-04-15 | 张自力 | 一种功能性营养素饮料 |
Also Published As
Publication number | Publication date |
---|---|
JPWO2007145239A1 (ja) | 2009-11-05 |
JP2015120715A (ja) | 2015-07-02 |
JP5775657B2 (ja) | 2015-09-09 |
KR20090019813A (ko) | 2009-02-25 |
WO2007145239A1 (ja) | 2007-12-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101454000A (zh) | 含有氨基酸组合物的抗疲劳剂 | |
US6462051B1 (en) | Composition for reducing mental fatigue, composition for maintaining and enhancing concentration, and composition for maintaining and enhancing mental vigor | |
CN101061860B (zh) | 富含亮氨酸的营养组合物 | |
US7288570B2 (en) | Stimulation of in vivo production of proteins | |
JP5798648B2 (ja) | アミノ酸組成物を含有する疲労防止剤 | |
US20120302513A1 (en) | Mitochondrial Function Improver | |
US20200108040A1 (en) | Agent for improving brain function and agent for preventing or treating cognitive impairment | |
BR0011277B1 (pt) | bebida desportiva compreendendo micronutrientes em combinação com aditivos convencionais para bebidas desportivas, tablete para a preparação de uma bebida desportiva e uso de lactobacilos. | |
US20210360958A1 (en) | Sleep-improving compositions | |
JP2006510367A (ja) | 血糖調節組成物 | |
US20120309716A1 (en) | Motor Function Improver | |
US20070196442A1 (en) | Method for improving the oral administration of alpha-lipoic acid | |
CA2528312C (en) | Methods of managing the symptoms of premenstrual syndrome | |
AU644866B2 (en) | High-protein high-viscosity alimentary food composition | |
EP3738590A1 (en) | Dietary supplement comprising amino acids for the treatment of sarcopenia | |
JP2021151223A (ja) | マイオカイン産生促進剤、筋出力増強剤、および筋芽細胞の分化促進剤 | |
JP2019099498A (ja) | 脂質代謝促進のための組成物 | |
Komorowski et al. | Inositol-Stabilized Arginine Silicate: A Novel Nitric Oxide-Boosting Ingredient for Sports Nutrition and Improved Cognition | |
JP2024053457A (ja) | 敏捷性の改善のための組成物 | |
FR2789552A1 (fr) | Composition synergique contenant de la glutamine-peptide et de la phosphatidylcholine pour son utilisation en dietetique | |
JP2019099497A (ja) | 肝機能改善のための組成物 | |
JP2019099495A (ja) | 血圧降下促進のための組成物 | |
JP2019034894A (ja) | 脂質代謝促進のための組成物 | |
JP2019058140A (ja) | 栄養組成物 | |
US20150264969A1 (en) | Nutritional Beverage Product |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1127730 Country of ref document: HK |
|
C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
WD01 | Invention patent application deemed withdrawn after publication |
Open date: 20090610 |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1127730 Country of ref document: HK |